Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Next Previous
X
Search
Trial Profile

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Jan 2020 Results (data cut off: December 31, 2016) assessing long-term efficacy and safety data from the trial after a median follow-up of 78.3 months published in the Cancer
    • 04 Dec 2018 Results after 5.7 years of follow up (n=22, data cut off: 30 Jun 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Jul 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top